AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) Sees Large Growth in Short Interest

AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) was the recipient of a large growth in short interest during the month of March. As of March 13th, there was short interest totaling 153,264 shares, a growth of 62.0% from the February 26th total of 94,590 shares. Based on an average daily trading volume, of 194,526 shares, the short-interest ratio is presently 0.8 days. Approximately 4.7% of the shares of the company are short sold.

AIM ImmunoTech Trading Up 1.2%

Shares of NYSEAMERICAN:AIM traded up $0.01 during mid-day trading on Friday, reaching $0.70. The company had a trading volume of 304,630 shares, compared to its average volume of 9,879,060. The firm has a market cap of $2.30 million, a price-to-earnings ratio of -0.03 and a beta of 1.26. The company’s 50-day moving average price is $0.98 and its 200-day moving average price is $1.58. AIM ImmunoTech has a one year low of $0.61 and a one year high of $36.00.

Analysts Set New Price Targets

Separately, Zacks Research downgraded AIM ImmunoTech from a “strong-buy” rating to a “hold” rating in a research report on Friday, February 6th. One equities research analyst has rated the stock with a Strong Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, AIM ImmunoTech has a consensus rating of “Buy”.

Institutional Investors Weigh In On AIM ImmunoTech

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Corient Private Wealth LLC bought a new position in AIM ImmunoTech during the second quarter worth about $87,000. Sabby Management LLC purchased a new position in shares of AIM ImmunoTech in the third quarter valued at $79,000. Finally, DRW Securities LLC raised its stake in shares of AIM ImmunoTech by 60.6% during the 4th quarter. DRW Securities LLC now owns 69,545 shares of the company’s stock valued at $79,000 after purchasing an additional 26,254 shares during the period. 12.02% of the stock is currently owned by institutional investors.

About AIM ImmunoTech

AIM ImmunoTech is a clinical-stage biotechnology company focused on the development and commercialization of immune-modulating therapies for the treatment of viral infections and cancer. The company’s lead product candidate, Ampligen (rintatolimod), is a proprietary toll-like receptor 3 (TLR3) agonist that aims to enhance the body’s innate immune response. AIM ImmunoTech’s research and development efforts center on demonstrating the safety and efficacy of Ampligen as both a standalone therapy and in combination with other treatments.

In addition to its oncology and antiviral programs, the company is advancing clinical trials of Ampligen in patients with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) and exploring potential applications for emerging viral threats.